Salk scientists reveal role of genetic switch in pigmentation and melanoma
Despite only accounting for about 1 percent of skin cancers, melanoma causes the majority of skin cancer-related deaths. While treatments for this serious disease do exist, these drugs can vary in effectiveness depending on the individual. A study by Professor Marc Montminy and Staff Scientist Jelena Ostojić reveals new insights about a protein called CRTC3, a genetic switch that could potentially be targeted to develop new treatments for melanoma by keeping the switch turned off.
Featured Stories
Interaction + Infrastructure = Innovations in Healthy AgingSalk formula recalculates aging research, shifting focus to overall resilience and health span.
Professor Jan Karlseder named Salk’s Chief Science OfficerOn February 1, Jan Karlseder started as Salk’s new senior vice president and chief science officer (CSO).
Salk mourns the loss of Nobel Laureate Roger GuilleminThe Institute remembers the “father of neuroendocrinology” for his many contributions to science and friendship to all.
Daniel Hollern–Turning a cancer diagnosis into a career in basic researchAssistant Professor Daniel Hollern pivoted his career trajectory after a family member’s life-changing diagnosis pushed his already-curious mind off a cliff of questions—starting with, “What can I do to help him?”
Jerry Sheehan–Collaborating shoulder to shoulder with scientistsWhen you think about a person who heads an information technology department, you might not envision them working shoulder to shoulder with research scientists. But that’s exactly the approach Jerry Sheehan is taking as Salk’s new chief information officer (CIO).
Laura Mainz–Taking control after a cancer diagnosisLaura Mainz grew up in a tiny village in midwestern Germany, with just as many cows as people. But the sweeping landscape speckled with farms never swayed her toward plant biology—instead, her interest in the human body grew.
Black Association affinity group cultivates welcoming environmentThe Black Association at Salk (BAS) was one of the first affinity groups formed at Salk in 2020. Since that time, it has established itself as a welcoming space and go-to for resources for all Black Salk community members.
Support a legacy where cures begin.
Scientific discovery at the Salk Institute is made possible through your annual contributions. Your support will accelerate the pace of breakthroughs in understanding disease and pave the way to new drug therapies.
Get involved